Highest-materiality recent filing
Beam Therapeutics Reports Q1 2026 Results; BEAM-302 Pivotal Cohort and Risto-cel BLA on Track
BEAM-302 Phase 1/2 data showed single-dose safety and efficacy; 60 mg selected as optimal dose; global pivotal cohort to start H2 2026.
Beam terminates license pact with Bio Palette; Kobe University standby license activated
Mutual termination of License Agreement with Bio Palette effective March 2, 2026 due to Bio Palette's planned dissolution.
Q4 net income $244.3M ($2.33 diluted EPS); full-year net loss $80.0M ($0.81 per share).
Beam Therapeutics secures standby direct license to Kobe University patents for base editing
Agreement dated Feb 9, 2026 among Beam, Bio Palette, and Kobe University ensures backup patent access.
Director Carole Ho resigns from Beam Therapeutics board effective Feb 27, 2026
Carole Ho notified resignation on Jan 31, 2026, effective Feb 27, 2026.
Estimated $1.25B cash, cash equivalents and marketable securities as of Dec 31, 2025; operating runway extended into 2029.
Beam Therapeutics nets $255.1M cash from sale of Orbital stake in BMS acquisition
Beam received $255.1M in closing cash plus up to ~$26.3M from escrow for its 75M shares (17% fully diluted) of Orbital.
Beam Q3 net loss $112.7M; cash $1.1B; BEAM-302 expands; Orbital acquisition by BMS
Net loss of $112.7M ($1.10 per share) in Q3 2025 vs $96.7M ($1.17 per share) in Q3 2024.
Beam Q2 net loss $102.3M; cash $1.2B; BEAM-302 17 patients dosed; BEAM-101 enrollment complete
Net loss of $102.3M ($1.00/share) vs $91.1M loss ($1.11/share) in Q2 2024; R&D expense rose to $101.8M.
Upfront consideration: 403,128 shares of BEAM common stock (~$6.86M based on $17.01 close).
Beam Therapeutics shareholders elect directors, ratify Deloitte, approve say-on-pay
Elected Mark Fishman (61.9M for, 10.3M against), Carole Ho (71.7M for), and Kathleen Walsh (71.9M for) as Class II directors.
Beam Q1 net loss $109.3M; cash $1.2B after $500M financing; clinical milestones hit
Net loss $109.3M ($1.24/share) vs $98.7M ($1.21/share) Q1 2024; R&D spend $98.8M.
BEAM-302 well tolerated at all doses; no serious AEs or dose-limiting toxicities observed.
Beam prices $500M underwritten offering of common stock and pre-funded warrants
Underwritten offering of 16,151,686 shares at $28.48 per share and pre-funded warrants for 1,404,988 shares at $28.47 each.
Beam Therapeutics reports Q4 net loss of $90.4M; cash $850.7M, clinical milestones reaffirmed
Net loss per share $1.09 in Q4 2024 vs net income of $1.77 in Q4 2023; full-year net loss $4.58 per share vs $1.72 in 2023.
Beam Therapeutics: $850.7M cash, pipeline progress, 2025 catalysts detailed
Preliminary cash, equivalents and marketable securities of $850.7M as of Dec 31, 2024; runway now into 2027 including BEAM-101 commercial readiness.
Seven patients dosed with BEAM-101 achieved HbF >60%, HbS <40%, and resolution of anemia; no VOCs post-engraftment.
Beam Therapeutics appoints Sravan Emany as CFO effective Dec 19, 2024
Sravan Emany previously CFO/COO of Ironwood Pharmaceuticals; also held roles at Integra, Bank of America, Goldman Sachs.
Beam Therapeutics appoints Chirfi Guindo to board of directors
Chirfi Guindo, chief marketing officer of Human Health at Merck, appointed to Beam's board.
Beam Therapeutics Q3 net loss $96.7M; cash $925.8M; BEAM-101 enrollment at 35 patients
Net loss $96.7M ($1.17/share) vs $96.1M ($1.22) Q3 2023; R&D $94.3M, G&A $26.5M.
Beam Therapeutics discusses Q3 results and ASH abstracts on investor call
Investor presentation covered Q3 financial results, but no specific figures provided in filing.
BEAM-101 (sickle cell disease): 4 patients engrafted, median 17 days neutrophil, 20 days platelet; HbF >60% by month 1.
Beam Therapeutics Q2 net loss $91.1M; cash $1.0B; BEAM-101 enrollment tops 20, six dosed
Net loss widened to $91.1M ($1.11/shr) from $82.8M ($1.08/shr) in Q2 2023.
CFO Terry-Ann Burrell resigns effective Aug 9, 2024 to join JPMorgan as vice chairman of investment banking.
Graham Cooper elected to board with 49.5M for, 6.5M against, 1.8M abstain, 8.4M broker non-votes.
Beam Therapeutics Q1 net loss $98.7M; BEAM-101 expansion cohort opened, cash $1.1B into 2027
Net loss of $98.7M ($1.21 per share) vs $96.5M ($1.33 per share) in Q1 2023.
Effective upon Ms. Burrell’s resignation, John Evans, the Company’s Chief Executive Officer and a member of the Company’s board of directors, was appointed Principal Financial and Accounting Officer of the Company.
Terry-Ann Burrell notified Beam Therapeutics Inc. (the “Company”) of her decision to resign as Chief Financial Officer and Treasurer of the Company, effective August 9, 2024, to pursue other opportunities.
Max materiality 0.85 · Median 0.70 · Most common event other_material